Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court Outcome Unlikely To Dent IPR Popularity

Executive Summary

The impact of an expected Supreme Court ruling to the US Patent & Trademark Office's Patent Trial and Appeal Board and its inter partes review process – proceedings intended to be faster and more affordable alternatives to challenging patents, versus pursuing litigation through the US court system – may not be as significant as the biopharmaceutical industry has been fretting over. The court heard oral arguments in the case, known as Cuozzo Speed v. Michelle Lee, on April 25. A decision is expected by the end of June.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC065045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel